The H5N1 avian flu vaccine this impressive approved use

[] Message: United States food and Drug Administration has approved the use of a kind used for human resistance of the H5N1 avian influenza virus vaccine. United States Government, the large reserves of this vaccine, to respond to possible human-to-human transmission of avian influenza.

Drug Authority said that the vaccine manufacturers from France vaccine sanofi-pasteur company based in the United States Pennsylvania factory production. The vaccine is not on sale, but by the United States Federal Government's direct procurement, into the United States national strategic reserves. Future in the event of large-scale human transmission of avian influenza, United States public health department is responsible for allocating issued.

The current H5N1 avian influenza virus is spread to many countries in the world. Since 2003, the world has about 300 people infected with this virus, more than half of them die. Drug Authority said that the future of the virus once variation can be spread from one person to another, Sanofi-Pasteur company production of vaccines in the outbreak occurred after the first few months to provide initial immune protection for your valuable time and development and production of new viruses for variation.

According to reports, this vaccine may 18 to 64-year-old crowd against H5N1 avian influenza virus vaccination immune protection, a total of twice the interval between intramuscular injection, about a month. The common side effects of vaccines included injection site pain, headache, muscle pain.